DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Almorexant
Almorexant
204569Orig1s000
Anti-Infectives Industry Over the Next 5 Years and Beyond
The Dual Orexin Receptor Antagonist TCS1102 Does Not Affect Reinstatement of Nicotine- Seeking
Annual HFHS Publications List 2017 This Bibliography Aims to Recognize
2017 Research Annual Report Table of Contents Summaries of 2017
Study Protocol
Understanding Peptide Binding in Class a G Protein-Coupled Receptors
Annual Report 2007 in Detail
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
A Multicentre Phase II Study of AZD1775 Plus Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer
Nonpublication of Trial Results for New Neurological Drugs: a Systematic Review
WO 2017/151816 Al 8 September 2017 (08.09.2017) P O P C T
The Use of Physiology-Based PK and PD Modeling in the Discovery of the Dual
Lemborexant for Insomnia
Stembook 2018.Pdf
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
MM&M Takes a Detailed Look at Key Products in the Pipeline
Hormonal Contraception in Women with Migraine
Top View
Identification of a Novel Series of Orexin Receptor
Actelion Presentation
Restructuring the Pharmaceutical Industry
The Dual Hypocretin Receptor Antagonist Almorexant Is Permissive for Activation of Wake-Promoting Systems
Research.Pdf (4.234Mb)
Hypocretin Receptor Antagonists for Insomnia: Rationale and Clinical Data
20 Years of Medicinal Chemistry Œ Always Look at the Bright Side
PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2011) (Rev
Prediction of Cyclosporin-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Model Characterizing Interplay of Drug Transporters and Enzymes
PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2016) Annotated for Statistical Reporting Purposes
Informed Consent Form – Group A
Dual'' Orexin Receptor Antagonists at OX1R and OX2R Orexin Receptors
The Roles of Orexins on Sleep/Wakefulness, Energy
Pharmacology and Toxicology
Pharmaabkommen A1 E
Kinetic Properties of "Dual'' Orexin Receptor Antagonists at OX1R And
Absence of Pharmacokinetic and Pharmacodynamic Interactions Between Almorexant and Warfarin in Healthy Subjects
The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468 S
(12) Patent Application Publication (10) Pub. No.: US 2010/0063141 A1 Seed Et Al
U.S. Pharmaceutical/Biotech Industry Update
WO 2008/055313 Al
Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
Event – Actelion Hoping New Data Will Build on Tracleer
WO 2015/120110 A2 13 August 2015 (13.08.2015) P O P C T
New Patents Expand Concert Pharmaceuticals' Patent Estate Of
Drug Repurposing Compound Library Plus (96-Well)
Targeting the Orexin System for Prescription Opioid Use Disorder
A Two-Tiered in Vitro Approach to De-Risk Drug Candidates for Potential Bile Salt Export Pump Inhibition Liabilities in Drug Discovery
A Novel Dual Orexin Receptor Antagonist S
Study Protocol AC-078A201
Study Protocol and Results
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Endocrinology
The Use of Physiology-Based PK and PD Modeling in the Discovery of the Dual
Phase II Proof-Of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder Kathryn M
BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
A Novel Dual Orexin Receptor Antagonist
Commitment to Performance to Commitment
Endocrinology Compound Library (96-Well)
(19) United States (12) Patent Application Publication (10) Pub
Are Neuropeptides Relevant for the Mechanism of Action of Ssris? T ⁎ Miłosz Gołyszny, Ewa Obuchowicz
Clemizole and Modulators of Serotonin Signalling Suppress Seizures in Dravet Syndrome
Preclinical in Vivo Characterization of Lemborexant (E2006)